Présentation de l'entreprise
Immunome, Inc. operates as a biotechnology entity focused on the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics within the United States market. The company is situated within the Healthcare sector, specifically the Biotechnology industry, an environment characterized by high capital requirements and a reliance on proprietary intellectual property to generate future revenue streams. As of the latest reporting period, the enterprise holds a market capitalization of $2.45 billion, with annual revenue generated in the trailing twelve months totaling $6.94 million, while employing a workforce of 177 individuals. These financial dimensions indicate that the company possesses a significant market valuation relative to its current revenue base, suggesting that the market price reflects substantial expectations regarding the potential success of its clinical pipeline assets, such as Varegacestat, rather than current operational profitability.
Santé financière
In its fiscal operations, Immunome, Inc. reported a revenue of $6.94 million over the trailing twelve months, yet it recorded a net income of -$212,394,000 and an EBITDA of -$211,647,008, highlighting a substantial structural gap where operating expenses and research costs vastly exceed current sales generation. The company generated free cash flow of -$133,619,624, which indicates a heavy reliance on external capital sources to fund its ongoing clinical trials and operational expenditures rather than internal cash generation. Regarding profitability metrics, the gross margin stands at 0.0%, the operating margin is -3084.8%, and the profit margin is 0.0%, collectively illustrating that the company is currently in a pre-revenue or early-stage loss-making phase typical of biotechnology firms before product approval. Despite the negative income, the firm maintains a cash position of $653.48 million against total debt of $3.85 million, resulting in a debt-to-equity ratio of 0.61, which suggests a balance sheet that is effectively unlevered regarding traditional debt obligations and heavily weighted toward cash reserves. This liquidity is further supported by a current ratio of 14.69, a figure that implies exceptional short-term solvency and the ability to meet obligations without difficulty. Finally, the return on equity is -52.1% and the return on assets is -29.0%, metrics that reveal that management is currently deploying capital to build long-term assets rather than generating immediate returns on the existing equity or asset base.
Évaluation de la valorisation
The valuation metrics for Immunome, Inc. present a complex picture, with a trailing P/E ratio listed as N/A and a forward P/E of -10.27, a divergence that implies the market is pricing in future earnings potential that is currently obscured by significant losses and negative projected earnings trajectories. The price-to-book ratio is recorded at 3.87, indicating that the company trades at a significant premium above its book value, which is common in biotechnology where intangible assets and pipeline value are not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 353.69 and an EV/EBITDA of -8.53 suggest that the market is valuing the company based on its strategic position and pipeline rather than traditional multiple expansion models. In terms of trading range, the stock has experienced a volatility between a 52-week high of $27.65 and a 52-week low of $5.15, with the current share price situated at a specific point within this wide band that reflects the high-risk, high-reward nature of the asset class. The beta of 2.14 further quantifies this risk profile, indicating that the stock's price volatility is more than twice that of the broader market, meaning it tends to amplify market movements significantly.
Growth & Income
The company's growth profile is currently defined by a revenue growth year-over-year of -100.0%, while earnings growth is marked as N/A due to the lack of recent positive earnings history, implying that the business model has not yet transitioned to a profitable state where earnings could outpace or lag revenue in a traditional sense. Immunome, Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the company retains all available capital to reinvest into its research and development efforts rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology firms in the discovery phase, where capital allocation is directed toward advancing clinical assets like Varegacestat rather than providing income to investors. Overall, the growth and income profile of Immunome, Inc. is characterized by zero current income distribution and negative revenue growth in the reported period, reflecting a company entirely dependent on future commercialization milestones to alter its trajectory from a cash-burning entity to a revenue-generating one.